Fundamentals To A Very Successful Future, page-119

Nothing new just a recent article if anyone is interested
https://smallcaps.com.au/cannabis-stocks-asx-ultimate-guide/
Medlab Clinical (ASX: MDC)

Australian medical life science company Medlab Clinical is focused on developing therapeutic pathways for diagnosed chronic diseases such as chronic kidney disease or pre-diabetes/obesity.

It is also researching new medicines for pain management and the treatment of depression and anti-aging, specifically musculoskeletal loss.

In September 2018, the company was granted a licence to export cannabis relating to the development of its NanaBis and NanaBidial cancer pain management medications, which are delivered in the form of an oral spray.

NanaBis is used to improve symptoms relating to intractable pain in cancer patients, while NanaBidial is used for chemotherapy-induced nausea and vomiting. NanaBidial has a secondary indication for patients suffering seizures.

In March 2019, the company announced it had teamed up with Canadian pharmaceutical company Pharmascience Inc for the further development and global distribution of NanaBis.

The announcement was followed by encouraging data from a stage 1 advanced cancer pain clinical trial, as well as case studies from Special Access Scheme use.

The clinical trial showed a faster absorption rate using the NanaBis spray compared to a tablet version. Meanwhile, the SAS case studies showed significant improvements in sleep and pain scores.